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Xeroderma pigmentosum (XP) is an autosomal
recessive genodermatosis caused by a germline loss
of function in DNA repair enzymes.1,2 This defect
impairs physiologic DNA repair after ultraviolet (UV)
radiationeinduced damage, which can lead to
photosensitivity in about half of all patients,3,4
pigmentation abnormalities, and an increased risk
of nonmelanoma skin cancers as well as melanoma.5
XP patients classically exhibit a 10,000-fold increase
in the frequency of skin cancers arising in sun-
exposed skin, eyes, and other mucosal areas (eg, lips
and tongue), which appear at an early age.5
Prognosis and mortality of XP patients are mostly
tightly related to the risk of metastasis of cutaneous
squamous cell carcinomas and melanomas but also
depend on the extent of the underlying DNA repair
deficiency. The life expectancy of XP patients is
reduced by 30 years.2,6
Seven genetically distinct complementation
groups of XP (designated XP-A through XP-G
depending on the gene mutated) with germline
loss of function mutations to enzymes are involved
in nucleotide excision repair (NER).6 The degree of
photosensitivity, risk of skin cancer, and risk of
neurologic abnormality vary from complementa-
tion group to group.3 XP complementation group Gthe Department of Dermatology, Peking Union Medical
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subtypes of XP with mutations identified in the
Excision Repair Cross-complementing Rodent
Repair Deficiency Complementation Group 5 gene
(ERCC5), which encodes an enzyme involved in the
incision step during the removal of UV-damaged
DNA. XP-G is one of the most clinically lethal
subtypes of XP, wherein patients also exhibit
clinical features of Cockayne syndrome (CS) or XP
with neurologic symptoms. To date, there have
been less than 20 XP-G cases reported in the
literature.7,8 Approximately 30 noncutaneous ma-
lignancies have also been associated with this lethal
XP subtype.9 Herein, we report a Chinese proband
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Fig 1. XP-G patient has multiple lentigines on arm.
Fig 2. XP-G patient has areas of poikiloderma at upper
chest and neck.
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tions in ERCC5—a nonsense mutation from the
father and a missense mutation from the mother.
To the best of our knowledge, this patient is the first
reported XP-G case identified in the Chinese
population.
CASE REPORT
Clinical history of proband patient
A 17-year-old Chinese girl, born to nonconsan-
guineous parents, was referred to our institution
for evaluation. She had multiple pigmented lesions
at the age of 3 years, which had progressively
increased in size and in number. The patient lived
in the northeastern part of China and received
minimal to moderate amounts of sun exposure.
There was no history of sun burns or sun sensi-
tivity and no family history of skin cancers.
Physical examination found a teenage girl who
appeared her stated age, measuring 165 cm in
height (60th percentile) and 60 kg in weight (72nd
percentile), and with a head circumference of 55
cm (25th-75th percentile).10 Cutaneous examina-
tion was notable for numerous pigmented mac-
ules, consistent with solar lentigines, on the
forearm (Fig 1), face, chest, and neck in a photo-
distributed manner (Fig 2) and hyperpigmentation
of the bilateral eyelids. External eye and fundo-
scopic examination results were within normal
limits, and she denied any history of visualizing
bright or dark floaters. The patient’s history was
also notable for significant photophobia and failing
to finish primary school due to poor memory.
Furthermore, neurologic evaluation also found
bilateral sensorineural deafness. Deep tendonreflexes were present. Computed tomography
scan of the brain found no evidence of significant
abnormality (eg, atrophy).
Cutaneous lentigines confirmed by shave
biopsy
Shave biopsies of several representative hyper-
pigmented macules on the face and arms found
epidermal acanthosis with elongated rete ridges and
hyperpigmentation of the basal layer keratinocytes
(Fig 3). Superficial dermal pigment incontinence was
also noted. The histologic findings were consistent
with solar lentigines.
Novel mutations identified by whole-exome
sequencing
Her overall clinical presentation was consistent
with XP. We were not able to pursue functional
studies to determine the complementation group
and to assay the activities of DNA repair enzymes,
because cell cultures were not available from the
proband or her family members. Therefore, genetic
testing with consent from the patient was performed
to identify the etiology. Whole-exome sequencing
(WES) was performed on the proband with analysis
restricted to known XP genes to avoid secondary
findings. In addition to the patient, the patient’s
parents also requested testing of themselves and
their younger daughter.
WES identified 2 novel compound heterozygous
mutations, c.[4G[T ];[697C[T ] (p.[Gly2Trp];[Gln233*])
in ERCC5 (NM_000123.3) in the proband. Familial
testing found that the patient inherited a nonsense
point mutation c.697C[T(p.(Gln233*)) in exon 7
from her father and a missense point mutation
c.4G[T(p.(Gly2Trp)) in exon 1 from her
mother. Only the maternal mutation was detected
in the unaffected sibling, consistent with an
autosomal recessive inheritance pattern (Fig 4).
Neither mutation has been seen in more than 7,800
East Asian chromosomes (exac.broadinstitute.org).
The paternal nonsense mutation is predicted to lead
Fig 3. Hematoxylin and eosinestained sections of face (A and B) and arm lesions (C and D).
Biopsy specimen shows acanthotic epidermis with elongated rate ridge and basal hyperpig-
mentation consistent with lentigo.
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nonsense-mediated decay. The maternally inherited
G to T transversion at the fourth position in the cDNA
is highly conserved at both DNA and amino acid
levels. This variant alters the Kozak consensus
sequence, which plays a major role in the initiation
of the translation process.11 Therefore, full-length
functional protein may be absent or significantly
reduced. If a residual amount of the full-length
protein is produced, the resulting p.Gly2Trp change
is still predicted to affect protein function by multiple
computational prediction tools (MutationAssessor,
MutationTaster, PolyPhen-2, and SIFT).12-15 The 2
mutations occur in trans in the proband; therefore,
both copies of the ERCC5 genes are affected, likely
resulting in significantly reduced activity of the
protein.
Management
The patient and her family were counseled
regarding the patient’s diagnosis and the importance
of minimizing sun exposure and the use of sun-
protective clothing and sun protection factor 301
sunscreen.
DISCUSSION
XP is a rare autosomal recessive, cancer-prone
genodermatosis characterized by a defective DNArepair after UV damage, resulting in a higher risk
of cutaneous malignancies, including basal cell
carcinomas, squamous cell carcinomas, and mela-
nomas in sun-exposed areas.2 Clinically, patients
can present with multiple, early-onset solar
lentigines with early development of senile,
photoaging-related changes. The histopathologic
criteria of certain XP skin lesions include hyper-
keratosis, chronic inflammation in the upper
dermis, and hyperpigmentation in the early stage
with basophilic degeneration of dermal collagen
bundles and solar elastosis in the papillary dermis
in the later stage. Intensive research of XP patient
skin samples has provided a critical disease model
for understanding the biologic relationship be-
tween UV exposure, point mutations, and the
development of skin cancers. Identifying the
defective NER mechanism in UV-irradiated cuta-
neous fibroblasts from XP patients has also led to
current understanding and classification of the
distinct 7 complementation groups (A-G) of this
disease.16
Although early diagnosis and treatment of XP
may be rendered based on typical clinical and
histopathologic features, genetic testing remains
one of the most important measures in making a
definitive diagnosis and managing patients
affected by XP. The genetic testing in this study
Fig 4. Pedigree chart of ERCC5 mutations. The c. nomen-
clature is based on the cDNA sequence, NM_000123.3, in
which the ‘‘A’’ in the ‘‘ATG’’ start codon is denoted number
1, and the p. nomenclature is based on the translated
protein. The patient has 2 compound heterozygous
mutations in ERCC5: a missense mutation in exon 1
(c.4G[T; p.Gly2Trp) inherited from her mother and a
nonsense mutation in exon 7 (c.697C[T; p.Gln233*)
inherited from her father. The patient’s unaffected parents
and younger sister are heterozygous carriers of only 1 of
the mutations.
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1 of the 2 compound heterozygous mutations,
leading to the expression of XP disease in the
proband. Taken together, we made a primary
diagnosis of XP based on the clinicopathologic
features and confirmed the diagnosis of XP-G by
genetic testing.17
The human ERCC5 gene contains 15 exons2,18
and encodes the XP-G protein, which participates
in the NER pathway by making incisions at the 39
end of damaged DNA to release a 25-27 nucleotide
DNA fragment containing the damaged photo-
product.18 Mutations resulting in markedly trun-
cated, inactive XP-G proteins are found in XP/CS
complex patients, whereas individuals with XP-G
without neurologic disease are found to have
missense mutations that retain some functional
activity.9,19 Although our patient does not meet
the diagnostic criteria for the XP/CS complex, her
overall clinical presentation is strongly suggestive
of some neurologic involvement. We hypothesize
that her unique phenotype may be caused by
residual functional activity resulting from the
missense variant, which may also impact protein
translation at the cDNA level.Although we determined the patient’s and her
familial genotypes, the biochemical functional
studies could not be pursued because the pa-
tient’s parents refused further biopsy and blood
sampling. The relationship between the identified
two mutations, the predicting amino acid changes,
and their functional relevance in UV damage
repair and neurologic function deserve further
investigation. In summary, we report the first XP-
G patient of Chinese extraction with 2 novel
germline mutations in the ERCC5 gene identified
by WES.
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